메뉴 건너뛰기




Volumn 31, Issue 12, 2008, Pages 1124-1131

The effects of insulin sensitizers on the cardiovascular risk factors in women with polycystic ovary syndrome

Author keywords

Cardiovascular risk factors; Insulin resistance; Metformin; PCOS; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIANDROGEN; BIGUANIDE DERIVATIVE; CLOMIFENE; CONTRACEPTIVE AGENT; INSULIN SENSITIZING AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

EID: 63049114314     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345663     Document Type: Review
Times cited : (7)

References (103)
  • 1
    • 0033345349 scopus 로고    scopus 로고
    • A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile
    • Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999, 84: 4006-11.
    • (1999) J Clin Endocrinol Metab , vol.84 , pp. 4006-4011
    • Diamanti-Kandarakis, E.1    Kouli, C.R.2    Bergiele, A.T.3
  • 3
    • 33751526500 scopus 로고    scopus 로고
    • Androgen Excess Society. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline
    • Azziz R, Carmina E, Dewailly D, et al. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006, 91: 4237-45.
    • (2006) J Clin Endocrinol Metab , vol.91 , pp. 4237-4245
    • Azziz, R.1    Carmina, E.2    Dewailly, D.3
  • 5
    • 0034979463 scopus 로고    scopus 로고
    • Concerted transcriptional activation of the low density lipoprotein receptor gene by insulin and luteinizing hormone in cultured porcine granulosa-luteal cells: Possible convergence of protein kinase a, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase signaling pathways
    • Sekar N, Veldhuis JD. Concerted transcriptional activation of the low density lipoprotein receptor gene by insulin and luteinizing hormone in cultured porcine granulosa-luteal cells: possible convergence of protein kinase a, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase signaling pathways. Endocrinology 2001, 142: 2921-8.
    • (2001) Endocrinology , vol.142 , pp. 2921-2928
    • Sekar, N.1    Veldhuis, J.D.2
  • 6
    • 0027200314 scopus 로고
    • Sites of inhibition of steroidogenesis by activation of protein kirrase-C in swine ovarian (granulosa) cells
    • Flores JA, Garmey JC, Nestler JE, Veldhuis JD. Sites of inhibition of steroidogenesis by activation of protein kirrase-C in swine ovarian (granulosa) cells. Endocrinology 1993, 132: 1983-90.
    • (1993) Endocrinology , vol.132 , pp. 1983-1990
    • Flores, J.A.1    Garmey, J.C.2    Nestler, J.E.3    Veldhuis, J.D.4
  • 7
    • 0030027986 scopus 로고    scopus 로고
    • The effect of insulin and insulin-like growth factors on the expression of steroidogenic enzymes in a human ovarian thecal-like tumor cell model
    • McGee EA, Sawetawan C, Bird I, Rainey WE, Carr B. The effect of insulin and insulin-like growth factors on the expression of steroidogenic enzymes in a human ovarian thecal-like tumor cell model. Fertil Steril 1996, 65: 87-93.
    • (1996) Fertil Steril , vol.65 , pp. 87-93
    • McGee, E.A.1    Sawetawan, C.2    Bird, I.3    Rainey, W.E.4    Carr, B.5
  • 8
    • 0034463967 scopus 로고    scopus 로고
    • Interactive stimulation by luteinizing hormone and insulin of the steroidogenic acute regulatory (StAR) protein and 17alpha-hydroxylase/17,20-lyase (CYP17) genes in porcine theca cells
    • Zhang G, Garmey JC, Veldhuis JD. Interactive stimulation by luteinizing hormone and insulin of the steroidogenic acute regulatory (StAR) protein and 17alpha-hydroxylase/17,20-lyase (CYP17) genes in porcine theca cells. Endocrinology 2000, 141: 2735-42.
    • (2000) Endocrinology , vol.141 , pp. 2735-2742
    • Zhang, G.1    Garmey, J.C.2    Veldhuis, J.D.3
  • 9
    • 33746220070 scopus 로고    scopus 로고
    • Molecular mechanisms of insulin resistance in polycystic ovary syndrome
    • Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006, 12: 324-32.
    • (2006) Trends Mol Med , vol.12 , pp. 324-332
    • Diamanti-Kandarakis, E.1    Papavassiliou, A.G.2
  • 10
    • 34548426625 scopus 로고    scopus 로고
    • Polycystic ovarian syndrome: The commonest cause of hyperandrogenemia in women as a risk factor for metabolic syndrome
    • Diamanti-Kandarakis E, Christakou C, Kandarakis H. Polycystic ovarian syndrome: the commonest cause of hyperandrogenemia in women as a risk factor for metabolic syndrome. Minerva Endocrinol 2007, 32: 35-47.
    • (2007) Minerva Endocrinol , vol.32 , pp. 35-47
    • Diamanti-Kandarakis, E.1    Christakou, C.2    Kandarakis, H.3
  • 11
    • 17444445125 scopus 로고    scopus 로고
    • Rizza RA. Androgen effect on insulin action and glucose metabolism. Mayo Clin Proc 2000, 75 8Suppl: S61-4.
    • Rizza RA. Androgen effect on insulin action and glucose metabolism. Mayo Clin Proc 2000, 75 8Suppl): S61-4.
  • 12
    • 0033767890 scopus 로고    scopus 로고
    • Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women
    • Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000, 20: 2414-21.
    • (2000) Arterioscler Thromb Vasc Biol , vol.20 , pp. 2414-2421
    • Talbott, E.O.1    Guzick, D.S.2    Sutton-Tyrrell, K.3
  • 13
    • 24344448639 scopus 로고    scopus 로고
    • Predictors of endothelial dysfunction in young women with polycystic ovary syndrome
    • Kravariti M, Naka KK, Kalantaridou SN, et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90: 5088-95.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 5088-5095
    • Kravariti, M.1    Naka, K.K.2    Kalantaridou, S.N.3
  • 17
    • 0035702475 scopus 로고    scopus 로고
    • Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome
    • Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001, 111: 607-13.
    • (2001) Am J Med , vol.111 , pp. 607-613
    • Legro, R.S.1    Kunselman, A.R.2    Dunaif, A.3
  • 18
    • 33846086155 scopus 로고    scopus 로고
    • Atherogenic lipoprotein phenotype and low-density lipoproteins size and sub-classes in women with polycystic ovary syndrome
    • Berneis K, Rizzo M, Lazzarini V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and sub-classes in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007, 92:186-9.
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 186-189
    • Berneis, K.1    Rizzo, M.2    Lazzarini, V.3    Fruzzetti, F.4    Carmina, E.5
  • 19
    • 33644558330 scopus 로고    scopus 로고
    • Cardiovascular disease in the polycystic ovary syndrome: New insights and perspectives
    • Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006, 185: 227-39.
    • (2006) Atherosclerosis , vol.185 , pp. 227-239
    • Cussons, A.J.1    Stuckey, B.G.2    Watts, G.F.3
  • 20
    • 21244477051 scopus 로고    scopus 로고
    • Pa ao lu H. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome
    • Yilmaz M, Biri A, Bukan N, Karakoç A, Sancak B, Törüner F, Pa ao lu H. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005, 20: 258-63.
    • (2005) Gynecol Endocrinol , vol.20 , pp. 258-263
    • Yilmaz, M.1    Biri, A.2    Bukan, N.3    Karakoç, A.4    Sancak, B.5    Törüner, F.6
  • 21
    • 33748708041 scopus 로고    scopus 로고
    • Inflammatory and endothelial markers in women with polycystic ovary syndrome
    • Diamanti-Kandarakis E, Alexandraki K, Piperi C, et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 2006, 36: 691-7.
    • (2006) Eur J Clin Invest , vol.36 , pp. 691-697
    • Diamanti-Kandarakis, E.1    Alexandraki, K.2    Piperi, C.3
  • 22
    • 0037326227 scopus 로고    scopus 로고
    • Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome
    • Orio F Jr, Palomba S, Di Biase S, et al. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003, 88: 673-9.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 673-679
    • Orio Jr, F.1    Palomba, S.2    Di Biase, S.3
  • 23
    • 2442434415 scopus 로고    scopus 로고
    • Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease
    • Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004, 89: 2160-5.
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 2160-2165
    • Boulman, N.1    Levy, Y.2    Leiba, R.3
  • 26
    • 38149040839 scopus 로고    scopus 로고
    • Asymmetric dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment
    • Heutling D, Schulz H, Nickel I, et al. Asymmetric dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008, 93: 82-90.
    • (2008) J Clin Endocrinol Metab , vol.93 , pp. 82-90
    • Heutling, D.1    Schulz, H.2    Nickel, I.3
  • 27
    • 38349111105 scopus 로고    scopus 로고
    • The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome
    • Charitidou C, Farmakiotis D, Zournatzi V, et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis 2008, 196: 958-65.
    • (2008) Atherosclerosis , vol.196 , pp. 958-965
    • Charitidou, C.1    Farmakiotis, D.2    Zournatzi, V.3
  • 28
    • 8844247151 scopus 로고    scopus 로고
    • The plasminogen activator system in young and lean women with polycystic ovary syndrome
    • Tarkun I, Cantürk Z, Arslan BC, Türemen E, Tarkun P. The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J 2004, 51: 467-72.
    • (2004) Endocr J , vol.51 , pp. 467-472
    • Tarkun, I.1    Cantürk, Z.2    Arslan, B.C.3    Türemen, E.4    Tarkun, P.5
  • 29
    • 0036323992 scopus 로고    scopus 로고
    • A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome
    • Kelly CJ, Lyall H, Petrie JR, et al. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2002, 87: 3287-90.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 3287-3290
    • Kelly, C.J.1    Lyall, H.2    Petrie, J.R.3
  • 30
    • 3242720491 scopus 로고    scopus 로고
    • The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels
    • Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004, 150: 793-8.
    • (2004) Eur J Endocrinol , vol.150 , pp. 793-798
    • Diamanti-Kandarakis, E.1    Palioniko, G.2    Alexandraki, K.3    Bergiele, A.4    Koutsouba, T.5    Bartzis, M.6
  • 31
    • 8744223271 scopus 로고    scopus 로고
    • Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome
    • Orio F Jr, Palomba S, Cascella T, et al. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome. Reprod Biomed Online 2004, 9: 505-10.
    • (2004) Reprod Biomed Online , vol.9 , pp. 505-510
    • Orio Jr, F.1    Palomba, S.2    Cascella, T.3
  • 32
    • 0002443834 scopus 로고    scopus 로고
    • Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS)
    • Atiomo WU, Fox R, Condon JE, et al. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2000, 52: 487-92.
    • (2000) Clin Endocrinol (Oxf) , vol.52 , pp. 487-492
    • Atiomo, W.U.1    Fox, R.2    Condon, J.E.3
  • 33
    • 34548319286 scopus 로고    scopus 로고
    • Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice
    • Devin JK, Johnson JE, Eren M, et al. Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice. J Mol Endocrinol 2007, 39: 9-16.
    • (2007) J Mol Endocrinol , vol.39 , pp. 9-16
    • Devin, J.K.1    Johnson, J.E.2    Eren, M.3
  • 34
    • 0034883317 scopus 로고    scopus 로고
    • Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease
    • Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 2001, 34: 407-13.
    • (2001) Clin Biochem , vol.34 , pp. 407-413
    • Sabuncu, T.1    Vural, H.2    Harma, M.3    Harma, M.4
  • 35
    • 0037707406 scopus 로고    scopus 로고
    • Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease
    • Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003, 80: 123-7.
    • (2003) Fertil Steril , vol.80 , pp. 123-127
    • Fenkci, V.1    Fenkci, S.2    Yilmazer, M.3    Serteser, M.4
  • 36
    • 35148846863 scopus 로고    scopus 로고
    • Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects
    • Uribarri J, Stirban A, Sander D, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 2007, 30: 2579-82.
    • (2007) Diabetes Care , vol.30 , pp. 2579-2582
    • Uribarri, J.1    Stirban, A.2    Sander, D.3
  • 37
    • 12944319290 scopus 로고    scopus 로고
    • Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome
    • Diamanti-Kandarakis E, Piperi C, Kalofoutis A. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005, 62: 37-43.
    • (2005) Clin Endocrinol (Oxf) , vol.62 , pp. 37-43
    • Diamanti-Kandarakis, E.1    Piperi, C.2    Kalofoutis, A.3
  • 38
    • 36849093893 scopus 로고    scopus 로고
    • Accumulation of dietary glycotoxins in the reproductive system of normal female rats
    • Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, et al. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med 2007, 85: 1413-20.
    • (2007) J Mol Med , vol.85 , pp. 1413-1420
    • Diamanti-Kandarakis, E.1    Piperi, C.2    Korkolopoulou, P.3
  • 39
    • 34249937629 scopus 로고    scopus 로고
    • Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries
    • Diamanti-Kandarakis E, Piperi C, Patsouris E, et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 2007, 127: 581-9.
    • (2007) Histochem Cell Biol , vol.127 , pp. 581-589
    • Diamanti-Kandarakis, E.1    Piperi, C.2    Patsouris, E.3
  • 41
    • 33750325774 scopus 로고    scopus 로고
    • Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents
    • Gilardini L, McTernan PG, Girola A, et al. Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis 2006, 189: 401-7.
    • (2006) Atherosclerosis , vol.189 , pp. 401-407
    • Gilardini, L.1    McTernan, P.G.2    Girola, A.3
  • 43
    • 10844279820 scopus 로고    scopus 로고
    • Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome
    • Spranger J, Möhlig M, Wegewitz U, et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004, 61: 738-46.
    • (2004) Clin Endocrinol (Oxf) , vol.61 , pp. 738-746
    • Spranger, J.1    Möhlig, M.2    Wegewitz, U.3
  • 44
    • 40349085646 scopus 로고    scopus 로고
    • Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome
    • Carmina E, Chu MC, Moran C, et al. Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome. Fertil Steril 2008, 89: 642-8.
    • (2008) Fertil Steril , vol.89 , pp. 642-648
    • Carmina, E.1    Chu, M.C.2    Moran, C.3
  • 45
    • 2942687834 scopus 로고    scopus 로고
    • Adiponectin: A novel adipokine linking adipocytes and vascular function
    • Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004, 89: 2563-8.
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 2563-2568
    • Goldstein, B.J.1    Scalia, R.2
  • 46
    • 36849025505 scopus 로고    scopus 로고
    • Early Metabolic derangements in daughters of women with polycystic ovary syndrome
    • Sir-Petermann T, Maliqueo M, Codner E, et al. Early Metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007, 92: 4637-42.
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 4637-4642
    • Sir-Petermann, T.1    Maliqueo, M.2    Codner, E.3
  • 47
    • 34548315745 scopus 로고    scopus 로고
    • The circulating PBEF/ NAMPT/visfatin level is associated with a beneficial blood lipid profile
    • Wang P, van Greevenbroek MM, Bouwman FG, et al. The circulating PBEF/ NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 2007, 454: 971-6.
    • (2007) Pflugers Arch , vol.454 , pp. 971-976
    • Wang, P.1    van Greevenbroek, M.M.2    Bouwman, F.G.3
  • 48
    • 34547672910 scopus 로고    scopus 로고
    • Increased plasma visfatin concentrations in women with polycystic ovary syndrome
    • Chan TF, Chen YL, Chen HH, Lee CH, Jong SB, Tsai EM. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril 2007, 88: 401-5.
    • (2007) Fertil Steril , vol.88 , pp. 401-405
    • Chan, T.F.1    Chen, Y.L.2    Chen, H.H.3    Lee, C.H.4    Jong, S.B.5    Tsai, E.M.6
  • 49
    • 34447336403 scopus 로고    scopus 로고
    • Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome
    • Kowalska I, Straczkowski M, Nikolajuk A, et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod 2007, 22: 1824-9.
    • (2007) Hum Reprod , vol.22 , pp. 1824-1829
    • Kowalska, I.1    Straczkowski, M.2    Nikolajuk, A.3
  • 50
    • 26244450785 scopus 로고    scopus 로고
    • Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease
    • Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005, 90: 5711-6.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 5711-5716
    • Meyer, C.1    McGrath, B.P.2    Teede, H.J.3
  • 51
    • 8744260883 scopus 로고    scopus 로고
    • Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome
    • Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89: 5454-61.
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 5454-5461
    • Talbott, E.O.1    Zborowski, J.V.2    Rager, J.R.3    Boudreaux, M.Y.4    Edmundowicz, D.A.5    Guzick, D.S.6
  • 52
    • 0033767890 scopus 로고    scopus 로고
    • Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women
    • Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000, 20: 2414-21.
    • (2000) Arterioscler Thromb Vasc Biol , vol.20 , pp. 2414-2421
    • Talbott, E.O.1    Guzick, D.S.2    Sutton-Tyrrell, K.3
  • 53
    • 0027080247 scopus 로고
    • Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women
    • Dahlgren E, Janson PO, Johansson S, Lapidus L, Odén A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992, 71: 599-604.
    • (1992) Acta Obstet Gynecol Scand , vol.71 , pp. 599-604
    • Dahlgren, E.1    Janson, P.O.2    Johansson, S.3    Lapidus, L.4    Odén, A.5
  • 54
    • 0033851421 scopus 로고    scopus 로고
    • Long-term consequences of polycystic ovary syndrome: Results of a 31 year follow-up study
    • Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 2000, 3: 101-5.
    • (2000) Hum Fertil (Camb) , vol.3 , pp. 101-105
    • Wild, S.1    Pierpoint, T.2    Jacobs, H.3    McKeigue, P.4
  • 55
    • 0034078044 scopus 로고    scopus 로고
    • Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: A retrospective cohort study
    • Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000, 52: 595-600.
    • (2000) Clin Endocrinol (Oxf) , vol.52 , pp. 595-600
    • Wild, S.1    Pierpoint, T.2    McKeigue, P.3    Jacobs, H.4
  • 57
    • 33745726758 scopus 로고    scopus 로고
    • Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome
    • Dagre A, Lekakis J, Mihas C, et al. Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome, Eur J Endocrinol 2006, 154: 883-90.
    • (2006) Eur J Endocrinol , vol.154 , pp. 883-890
    • Dagre, A.1    Lekakis, J.2    Mihas, C.3
  • 58
    • 41749103363 scopus 로고    scopus 로고
    • Serum concentrations of atherogenic proteins Neutrophil gelatinase-associated lipocalin and its complex with Matrix Metalloproteinase-9 are significantly lower in women with Polycystic Ovary Syndrome: Hint of a protective mechanism?
    • Diamanti-Kandarakis E, Livadas S, Kandarakis S, Margeli A, Papassotiriou I. Serum concentrations of atherogenic proteins Neutrophil gelatinase-associated lipocalin and its complex with Matrix Metalloproteinase-9 are significantly lower in women with Polycystic Ovary Syndrome: Hint of a protective mechanism? Eur J Endocrinol 2008, 158: 525-31.
    • (2008) Eur J Endocrinol , vol.158 , pp. 525-531
    • Diamanti-Kandarakis, E.1    Livadas, S.2    Kandarakis, S.3    Margeli, A.4    Papassotiriou, I.5
  • 59
    • 0031957333 scopus 로고    scopus 로고
    • Therapeutic effects of metformin on insulin resistance and hyper-androgenism in polycystic ovary syndrome
    • Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyper-androgenism in polycystic ovary syndrome. Eur J Endocrinol 1998, 138: 269-74.
    • (1998) Eur J Endocrinol , vol.138 , pp. 269-274
    • Diamanti-Kandarakis, E.1    Kouli, C.2    Tsianateli, T.3    Bergiele, A.4
  • 61
    • 0031456016 scopus 로고    scopus 로고
    • Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis
    • Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18: 774-800.
    • (1997) Endocr Rev , vol.18 , pp. 774-800
    • Dunaif, A.1
  • 62
    • 0030855145 scopus 로고    scopus 로고
    • Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
    • Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997, 82: 2108-16.
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 2108-2116
    • Ehrmann, D.A.1    Schneider, D.J.2    Sobel, B.E.3
  • 63
    • 0038508940 scopus 로고    scopus 로고
    • Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome
    • Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003, 18: 1210-8.
    • (2003) Hum Reprod , vol.18 , pp. 1210-1218
    • Romualdi, D.1    Guido, M.2    Ciampelli, M.3    Giuliani, M.4    Leoni, F.5    Perri, C.6    Lanzone, A.7
  • 64
    • 33749035259 scopus 로고    scopus 로고
    • Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: A randomized placebo-controlled study
    • Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod 2006, 21: 1400-7.
    • (2006) Hum Reprod , vol.21 , pp. 1400-1407
    • Rautio, K.1    Tapanainen, J.S.2    Ruokonen, A.3    Morin-Papunen, L.C.4
  • 65
    • 18744362198 scopus 로고    scopus 로고
    • Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: A randomized study
    • Kilicdag EB, Bagis T, Zeyneloglu HB, et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 2005, 20: 894-9.
    • (2005) Hum Reprod , vol.20 , pp. 894-899
    • Kilicdag, E.B.1    Bagis, T.2    Zeyneloglu, H.B.3
  • 66
    • 35448981431 scopus 로고    scopus 로고
    • The effect of rosiglitazone on plasma adiponectin and resistin levels in obese PCO woman-preliminary report
    • Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A. The effect of rosiglitazone on plasma adiponectin and resistin levels in obese PCO woman-preliminary report. Przegl Lek 2007, 64: 70-3.
    • (2007) Przegl Lek , vol.64 , pp. 70-73
    • Jakubowska, J.1    Bohdanowicz-Pawlak, A.2    Milewicz, A.3
  • 67
    • 28544441286 scopus 로고    scopus 로고
    • The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome
    • Yilmaz M, Bukan N, Ayvaz G, et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 2005, 20: 3333-40.
    • (2005) Hum Reprod , vol.20 , pp. 3333-3340
    • Yilmaz, M.1    Bukan, N.2    Ayvaz, G.3
  • 68
    • 34249665044 scopus 로고    scopus 로고
    • Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy
    • Orbetsova M, Kamenov Z, Kolarov G, et al. Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy. Akush Ginekol (Sofiia) 2006, 45: 16-28.
    • (2006) Akush Ginekol (Sofiia) , vol.45 , pp. 16-28
    • Orbetsova, M.1    Kamenov, Z.2    Kolarov, G.3
  • 69
    • 23844436916 scopus 로고    scopus 로고
    • Metformin and weight loss in obese women with polycystic ovary syndrome: Comparison of doses
    • Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005, 90: 4593-8.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 4593-4598
    • Harborne, L.R.1    Sattar, N.2    Norman, J.E.3    Fleming, R.4
  • 70
    • 33846875851 scopus 로고    scopus 로고
    • Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
    • Legro RS, Barnhart HX, Schlaff WD, et al; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007, 356: 551-66.
    • (2007) N Engl J Med , vol.356 , pp. 551-566
    • Legro, R.S.1    Barnhart, H.X.2    Schlaff, W.D.3
  • 71
    • 29144477303 scopus 로고    scopus 로고
    • Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study
    • Tang T, Glanville J, Hayden CJ, White D, Barth JH, balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006, 21: 80-9.
    • (2006) Hum Reprod , vol.21 , pp. 80-89
    • Tang, T.1    Glanville, J.2    Hayden, C.J.3    White, D.4    Barth, J.H.5    balen, A.H.6
  • 72
    • 33745512819 scopus 로고    scopus 로고
    • The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome - a randomised, double-blind, placebo-controlled trial
    • Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome - a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynaecol 2006, 113: 817-24.
    • (2006) Br J Obstet Gynaecol , vol.113 , pp. 817-824
    • Lord, J.1    Thomas, R.2    Fox, B.3    Acharya, U.4    Wilkin, T.5
  • 73
    • 34347362939 scopus 로고    scopus 로고
    • Metformin and glitazones: Do they really help PCOS patients?
    • Pillai A, Bang H, Green C. Metformin and glitazones: do they really help PCOS patients? J Fam Pract 2007, 56: 444-53.
    • (2007) J Fam Pract , vol.56 , pp. 444-453
    • Pillai, A.1    Bang, H.2    Green, C.3
  • 74
    • 5144220551 scopus 로고    scopus 로고
    • Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity
    • Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004, 82: 893-902.
    • (2004) Fertil Steril , vol.82 , pp. 893-902
    • Baillargeon, J.P.1    Jakubowicz, D.J.2    Iuorno, M.J.3    Jakubowicz, S.4    Nestler, J.E.5
  • 75
    • 15944390236 scopus 로고    scopus 로고
    • Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome
    • Ortega-González C, Luna S, Hernández L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90: 1360-5.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 1360-1365
    • Ortega-González, C.1    Luna, S.2    Hernández, L.3
  • 76
    • 85036842599 scopus 로고    scopus 로고
    • Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007, 19: 402.e1-11.
    • Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007, 19: 402.e1-11.
  • 77
    • 0028315971 scopus 로고
    • Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
    • Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994, 43: 647-54.
    • (1994) Metabolism , vol.43 , pp. 647-654
    • Velazquez, E.M.1    Mendoza, S.2    Hamer, T.3    Sosa, F.4    Glueck, C.J.5
  • 78
    • 0034458234 scopus 로고    scopus 로고
    • Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
    • Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000, 85: 139-46.
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 139-146
    • Moghetti, P.1    Castello, R.2    Negri, C.3
  • 79
    • 14644406278 scopus 로고    scopus 로고
    • Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome
    • Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2005, 152: 269-75.
    • (2005) Eur J Endocrinol , vol.152 , pp. 269-275
    • Rautio, K.1    Tapanainen, J.S.2    Ruokonen, A.3    Morin-Papunen, L.C.4
  • 80
    • 34547406316 scopus 로고    scopus 로고
    • Metformin administration improves leukocyte count in women with polycystic ovary syndrome: A 6-month prospective study
    • Orio F, Manguso F, Di Biase S, et al. Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. Eur J Endocrinol 2007, 157: 69-73.
    • (2007) Eur J Endocrinol , vol.157 , pp. 69-73
    • Orio, F.1    Manguso, F.2    Di Biase, S.3
  • 82
    • 36249013118 scopus 로고    scopus 로고
    • The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome
    • Sahin Y, Unluhizarci K, Yilmazsoy A, Yikilmaz A, Aygen E, Kelestimur F. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007, 67: 904-8.
    • (2007) Clin Endocrinol (Oxf) , vol.67 , pp. 904-908
    • Sahin, Y.1    Unluhizarci, K.2    Yilmazsoy, A.3    Yikilmaz, A.4    Aygen, E.5    Kelestimur, F.6
  • 83
    • 0142247208 scopus 로고    scopus 로고
    • Metformin in polycystic ovary syndrome: Systematic review and meta-analysis
    • Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003, 327: 951-3.
    • (2003) BMJ , vol.327 , pp. 951-953
    • Lord, J.M.1    Flight, I.H.2    Norman, R.J.3
  • 84
    • 22844445332 scopus 로고    scopus 로고
    • Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome
    • Tarkun I, Cetinarslan B, Türemen E, Sahini T, Cantürk Z, Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 2005, 153: 115-21.
    • (2005) Eur J Endocrinol , vol.153 , pp. 115-121
    • Tarkun, I.1    Cetinarslan, B.2    Türemen, E.3    Sahini, T.4    Cantürk, Z.5    Komsuoglu, B.6
  • 85
    • 25844467331 scopus 로고    scopus 로고
    • Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance
    • Lv L, Liu Y. Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance. J Huazhong Univ Sci Technolog Med Sci 2004, 24: 480-2.
    • (2004) J Huazhong Univ Sci Technolog Med Sci , vol.24 , pp. 480-482
    • Lv, L.1    Liu, Y.2
  • 86
    • 0037326410 scopus 로고    scopus 로고
    • Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome
    • Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003, 88: 576-80.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 576-580
    • Paradisi, G.1    Steinberg, H.O.2    Shepard, M.K.3    Hook, G.4    Baron, A.D.5
  • 87
    • 0344442676 scopus 로고    scopus 로고
    • Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone
    • Legro RS, Azziz R, Ehrmann D, Fereshetian AG, O'Keefe M, et al. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 2003, 88: 5137-44.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 5137-5144
    • Legro, R.S.1    Azziz, R.2    Ehrmann, D.3    Fereshetian, A.G.4    O'Keefe, M.5
  • 88
    • 7044253431 scopus 로고    scopus 로고
    • A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
    • Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004, 164: 2097-104.
    • (2004) Arch Intern Med , vol.164 , pp. 2097-2104
    • Chiquette, E.1    Ramirez, G.2    Defronzo, R.3
  • 89
    • 0042624707 scopus 로고    scopus 로고
    • Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin
    • Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003, 18: 1618-25.
    • (2003) Hum Reprod , vol.18 , pp. 1618-1625
    • Glueck, C.J.1    Moreira, A.2    Goldenberg, N.3    Sieve, L.4    Wang, P.5
  • 90
    • 0034748334 scopus 로고    scopus 로고
    • Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy
    • Diamanti-Kandarakis E, Spine G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001, 86: 4666-73.
    • (2001) J Clin Endocrinol Metab , vol.86 , pp. 4666-4673
    • Diamanti-Kandarakis, E.1    Spine, G.2    Kouli, C.3    Migdalis, I.4
  • 91
    • 19744365285 scopus 로고    scopus 로고
    • Metformin administration improves endothelial function in women with polycystic ovary syndrome
    • Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005, 152: 749-56.
    • (2005) Eur J Endocrinol , vol.152 , pp. 749-756
    • Diamanti-Kandarakis, E.1    Alexandraki, K.2    Protogerou, A.3
  • 92
    • 27744599917 scopus 로고    scopus 로고
    • Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: Results of a 6-month study
    • Orio F Jr, Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005, 90: 6072-6.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 6072-6076
    • Orio Jr, F.1    Palomba, S.2    Cascella, T.3
  • 93
    • 0037242513 scopus 로고    scopus 로고
    • Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: A randomized study
    • Morin Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003, 88: 148-56.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 148-156
    • Morin Papunen, L.1    Vauhkonen, I.2    Koivunen, R.3    Ruokonen, A.4    Martikainen, H.5    Tapanainen, J.S.6
  • 94
    • 33745621423 scopus 로고    scopus 로고
    • Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin
    • Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006, 21: 1426-31.
    • (2006) Hum Reprod , vol.21 , pp. 1426-1431
    • Diamanti-Kandarakis, E.1    Paterakis, T.2    Alexandraki, K.3
  • 95
    • 2342532378 scopus 로고    scopus 로고
    • The polycystic ovary syndrome per se is not associated with increased chronic inflammation
    • Möhlig M, Spranger J, Osterhoff M, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004, 150: 525-32.
    • (2004) Eur J Endocrinol , vol.150 , pp. 525-532
    • Möhlig, M.1    Spranger, J.2    Osterhoff, M.3
  • 97
    • 20744435927 scopus 로고    scopus 로고
    • Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: A randomized trial
    • Kilicdag EB, Bagis T, Tarim E, et al. Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial. Hum Reprod 2005, 20: 1521-8.
    • (2005) Hum Reprod , vol.20 , pp. 1521-1528
    • Kilicdag, E.B.1    Bagis, T.2    Tarim, E.3
  • 98
    • 33845217088 scopus 로고    scopus 로고
    • Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome
    • Diamanti-Kandarakis E, Alexandraki K, Piperi C, et al. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism 2007, 56: 129-34.
    • (2007) Metabolism , vol.56 , pp. 129-134
    • Diamanti-Kandarakis, E.1    Alexandraki, K.2    Piperi, C.3
  • 99
    • 33947714047 scopus 로고    scopus 로고
    • Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: A randomized placebo-controlled study
    • Majuri A, Santaniemi M, Rautio K, et al. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 2007, 156: 263-9.
    • (2007) Eur J Endocrinol , vol.156 , pp. 263-269
    • Majuri, A.1    Santaniemi, M.2    Rautio, K.3
  • 100
    • 38049177902 scopus 로고    scopus 로고
    • Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome
    • Glintborg D, Frystyk J, Højlund K, et al. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2008, 68: 165-74.
    • (2008) Clin Endocrinol (Oxf) , vol.68 , pp. 165-174
    • Glintborg, D.1    Frystyk, J.2    Højlund, K.3
  • 101
    • 15444366255 scopus 로고    scopus 로고
    • Polycystic ovary syndrome
    • Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005, 352: 1223-36.
    • (2005) N Engl J Med , vol.352 , pp. 1223-1236
    • Ehrmann, D.A.1
  • 102
    • 42049083794 scopus 로고    scopus 로고
    • postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation
    • Shaw LJ, Bairey Merz CN, Azziz R, et al. postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008, 93: 1276-84.
    • (2008) J Clin Endocrinol Metab , vol.93 , pp. 1276-1284
    • Shaw, L.J.1    Bairey Merz, C.N.2    Azziz, R.3
  • 103
    • 42449144300 scopus 로고    scopus 로고
    • Drug insight: Insulin-sensitizing drugs in the treatment of polycystic ovary syndrome - a reappraisal
    • Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome - a reappraisal. Nat Clin Pract Endocrinol Metab 2008, 4: 272-83.
    • (2008) Nat Clin Pract Endocrinol Metab , vol.4 , pp. 272-283
    • Dunaif, A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.